Article
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
2 Dec 2019
Abstract excerpt
The current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi , its Wolbachia endosymbiont w Bm, and its vector host Aedes aegypti at 16 distinct B. malayi life stages. B. malayi upregulates...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
